Tuesday , May 24 2022

Developed a drug that reduces risk …


However, the medication class, called SGLT2 inhibitors, did not show any statistically significant advantages for patients with cardiovascular disease, even for heart or stroke attacks.

Diabeticists increase the risk of heart disease, which enables the heart to cater to doctors and patients.

Brigadier Stephen Viviot and Boston's Woman's Hospital, a senior investigator in this cynical study, said these findings are important in making a clear picture of the drugs that have been detected for patients with SGLT2 diagnosis.

AstraZeneca hopes that new data will help expand the Farhadi to a wide range of patients.

The key findings of the 17,000 Clinical Census Declaration were published in September, but reported on Saturday at the annual American Heart Association annual meeting, and at the same time published in the New York Medical Journal.

These results show that Pharmacia has 27% of the risk of hospitalization due to heart problems and reduces the risk of renal disease.

However, while two subgroups using competing SGLT2 concentrate on patients diagnosed with cardiac diagnosis, Viviott said that the overall picture of this statement showed that the heart attack was the first occurrence.

"By analyzing three studies, the main advantage of this class of cardiovascular diseases is to reduce heart failure," said Viviot.

For decades, diabetologists have focused on reducing blood glucose levels at a certain level. Adaptation to diabetic problems, such as heart failure, indicates that the five-year survival rate is only 50%, "says Viviotte.

"Reduction of glucose levels may be important in the proportion we have made. We have to choose not only effective drugs to reduce blood glucose, but also improve the life expectancy of patients, "said the doctor.

Farkhiga E. Lilly and Bohrringer Inghelheim and Invomana Johnson & Johnson, Jardiance, compete with their competing SGLT2 drugs, increasing the lifetime of patients with heart failure diagnosis called repeating prevention.

AstraZeneca's research, after evaluating patients with no diagnosis of cardiovascular disease, reveals a wider market that includes primary prevention.

The Declare study did not reveal the increased risk of amputation, fractures, urea or gangrene in patients treated in Farsi, and the problems observed in patients treated with SLLT, but increased sexual infections.

Source link